Twist Bioscience Co. (NASDAQ:TWST) Given Average Recommendation of "Moderate Buy" by Analysts

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $51.78.

Several research firms have recently weighed in on TWST. Barclays reduced their price objective on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a research report on Tuesday. Robert W. Baird upped their target price on Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a research note on Tuesday. Scotiabank raised their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a report on Tuesday. Evercore ISI lifted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. lifted their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a research report on Monday, August 5th.

Twist Bioscience Trading Down 0.3 %

Twist Bioscience stock traded down $0.11 during trading hours on Tuesday, reaching $41.32. 1,235,872 shares of the company were exchanged, compared to its average volume of 953,744. The firm has a market cap of $2.42 billion, a price-to-earnings ratio of -10.74 and a beta of 1.78. The stock has a 50-day moving average of $43.98 and a 200 day moving average of $46.18. Twist Bioscience has a 12 month low of $23.00 and a 12 month high of $60.90.

Insiders Place Their Bets

In other news, insider Dennis Cho sold 1,507 shares of the business's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $72,336.00. Following the sale, the insider now owns 91,163 shares of the company's stock, valued at $4,375,824. The trade was a 1.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Robert F. Werner sold 1,448 shares of the company's stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total transaction of $64,580.80. Following the sale, the chief accounting officer now directly owns 45,620 shares in the company, valued at $2,034,652. This trade represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 98,118 shares of company stock worth $4,391,151. Corporate insiders own 3.92% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Signaturefd LLC grew its position in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after purchasing an additional 306 shares during the last quarter. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience during the 2nd quarter valued at about $43,000. Blue Trust Inc. boosted its holdings in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after acquiring an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Twist Bioscience in the second quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after acquiring an additional 381 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.